GO
Loading...

Gilead Sciences Inc

More

  • NEW YORK, July 29- With some of Wall Street's more volatile names set to report in the next couple of days, traders who bet on big swings in shares are hoping to see moves more like Facebook than Netflix. Netflix, along with Gilead Sciences and several other stocks famous for their sharp gyrations, were unusually calm following their latest quarterly reports.

  • Investors more wary over tech stock run Monday, 28 Jul 2014 | 10:12 AM ET
    Trader on the floor of the New York Stock Exchange.

    Many so-called momentum stocks have rebounded as economic data have been mixed and volatility remained low. Financial Times reports.

  • Europe backs new leukemia drugs from J&J and Gilead Friday, 25 Jul 2014 | 7:20 AM ET

    LONDON, July 25- Two new leukemia drugs from Johnson& Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib.

  • Your first trade for Friday Thursday, 24 Jul 2014 | 1:39 PM ET

    The "Fast Money" traders share their final trades of the day.

  • July 24- Celgene Corp reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.

  • Early movers: GM, F, CAT, AAL, JPM, FB, T & more Thursday, 24 Jul 2014 | 8:05 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • July 23- Gilead Sciences Inc said on Wednesday that its new hepatitis C drug Sovaldi had sales of $3.5 billion in the second quarter, demonstrating that the furor over its price has not curtailed early use. Since its December launch, Sovaldi has been prescribed for more than 80,000 patients in the United States and Europe, the company said.

  • Aced the SAT? Try this Cramer question Wednesday, 23 Jul 2014 | 6:19 PM ET

    If you have a penchant for quizzes and such, Jim Cramer thinks this question could lead you to a solid stock idea.

  • After-hours buzz: Facebook, AT&T, Gilead & more Wednesday, 23 Jul 2014 | 5:15 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Check out which companies are making headlines after the bell Wednesday: Facebook, AT&T, Gilead & more.

  • July 23- The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer. The FDA approved the use of Zydelig in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia.

  • As S&P nears 2,000, traders say keep an eye on this Wednesday, 23 Jul 2014 | 9:48 AM ET
    Traders work the floor of the New York Stock Exchange.

    Shaking off geopolitical flare-ups for now, analysts say the S&P 500 is taking aim at the 2,000 level, and the next round of earnings news could help.

  • Politics fade as earnings take over Friday, 18 Jul 2014 | 6:30 PM ET
    Espirito Santo International is the parent company of several institutions, including Banco Espirito Santo.

    Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.

  • Midday movers: Blackstone, GE, RealPage & More Friday, 18 Jul 2014 | 12:44 PM ET
    Trader on the floor of the New York Stock Exchange.

    Some of Friday's midday movers:

  • July 17- UnitedHealth Group Inc, after wading cautiously into Obamacare insurance exchanges this year, on Thursday vowed to become a major player, participating in as many as two dozen state exchanges in 2015 and growing from there.

  • Sovaldi—$55 billion headache for states Thursday, 17 Jul 2014 | 10:18 AM ET

    States may be on the hook for $55 billion to pay for hepatitis C treatments like Sovaldi, a new study says.

  • July 15- Johnson& Johnson reported higher-than-expected quarterly revenue and earnings, benefiting from strong sales of its Olysio treatment for hepatitis C. Sales jumped 9.1 percent to $19.5 billion, beating Wall Street expectations of $18.99 billion.

  • This liver disease could rival hepatitis C Tuesday, 15 Jul 2014 | 8:06 AM ET

    The liver disease NASH is becoming more widespread, and the market for treatments may rival those for hepatitis C.

  • Allergan to shareholders: Ignore Pershing Square Friday, 11 Jul 2014 | 6:31 PM ET
    A vial of Allergan’s Botox is arranged next to boxes for a photograph at a doctor's office in Manhattan Beach, Calif.

    Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.

  • Midday movers: Amazon.com, Ford Motor, URS & More Friday, 11 Jul 2014 | 1:04 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Friday's midday movers:

  • July 11- Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough treatment for hepatitis C, citing the expense to federal healthcare programs.